Abivax SA Sponsored ADR (NASDAQ:ABVX) Receives Consensus Rating of “Moderate Buy” from Brokerages

Shares of Abivax SA Sponsored ADR (NASDAQ:ABVX) have earned an average recommendation of “Moderate Buy” from the thirteen research firms that are covering the stock, Marketbeat.com reports. One investment analyst has rated the stock with a sell recommendation, eleven have issued a buy recommendation and one has given a strong buy recommendation to the company. The average 1-year target price among brokers that have issued ratings on the stock in the last year is $134.75.

Several analysts have weighed in on ABVX shares. Guggenheim reaffirmed a “buy” rating and issued a $175.00 price target on shares of Abivax in a report on Thursday, December 18th. Citizens Jmp raised their target price on shares of Abivax from $114.00 to $131.00 and gave the company a “market outperform” rating in a research note on Tuesday, December 16th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Abivax in a research report on Wednesday, January 21st. Piper Sandler reissued an “overweight” rating and issued a $142.00 price target on shares of Abivax in a report on Tuesday, December 16th. Finally, BTIG Research restated a “buy” rating and set a $150.00 price objective on shares of Abivax in a research report on Wednesday, February 25th.

Abivax Trading Up 5.1%

Shares of ABVX opened at $116.77 on Thursday. Abivax has a fifty-two week low of $4.77 and a fifty-two week high of $148.83. The business has a 50-day moving average of $122.61 and a 200 day moving average of $106.99. The firm has a market cap of $9.23 billion, a P/E ratio of -27.94 and a beta of 1.00. The company has a debt-to-equity ratio of 0.03, a quick ratio of 7.86 and a current ratio of 7.86.

Abivax (NASDAQ:ABVX) last posted its earnings results on Monday, December 15th. The company reported ($2.46) earnings per share (EPS) for the quarter. The business had revenue of ($4.92) million during the quarter. As a group, research analysts forecast that Abivax will post -2.83 EPS for the current year.

Institutional Investors Weigh In On Abivax

A number of hedge funds and other institutional investors have recently modified their holdings of ABVX. EverSource Wealth Advisors LLC lifted its holdings in shares of Abivax by 4,612.5% during the third quarter. EverSource Wealth Advisors LLC now owns 377 shares of the company’s stock valued at $32,000 after purchasing an additional 369 shares during the last quarter. First Horizon Corp bought a new position in shares of Abivax during the third quarter valued at $36,000. Bank of America Corp DE increased its holdings in shares of Abivax by 56.1% during the fourth quarter. Bank of America Corp DE now owns 5,536 shares of the company’s stock valued at $41,000 after acquiring an additional 1,990 shares in the last quarter. Hantz Financial Services Inc. purchased a new position in shares of Abivax in the 3rd quarter worth about $52,000. Finally, Caitong International Asset Management Co. Ltd boosted its stake in Abivax by 661.5% in the 4th quarter. Caitong International Asset Management Co. Ltd now owns 396 shares of the company’s stock worth $53,000 after purchasing an additional 344 shares in the last quarter. Institutional investors own 47.91% of the company’s stock.

About Abivax

Founded in 2013 and headquartered in Paris, France, Abivax is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for chronic inflammatory diseases and viral infections. The company’s technology platform targets host RNA biogenesis to modulate key immune pathways, offering a differentiated approach aimed at disease modification and improved safety profiles.

Abivax’s lead clinical asset, obefazimod (ABX464), is being evaluated in ulcerative colitis and other inflammatory disorders.